A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Фаза 2 – изследване на ефективността и дозировката
Заболявания:
Myasthenia Gravis, Generalized
Спонсор: Vertex Pharmaceuticals Incorporated
Налично на:
БГ
Обобщение
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
Кой може да участва
Key Inclusion Criteria:
* Age 18-80 years
* Diagnosis of generalized myasthenia gravis with generalized muscle weakness and fitting MGFA clinical classification II-IV
* Additional inclusion criteria are defined in the protocol
Key Exclusion Criteria:
* History of thymic surgery within 6 months of screening
* History of malignancy within the last 5 years
* Additional exclusion criteria are defined in the protocol
Other protocol defined Inclusion/Exclusion criteria will apply.
БГ
EN